Biotech On Track To Develop Bio-Synthetic Cannabinoids

InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF) released news Sept 25, 2017 revealing that the company had made breakthroughs in the scale-up and commercialization of the biosynthesis process for cannabinoid production.

IN/IMLFF noted that it can selectively produce all four “gateway” cannabinoids using genetically engineered microorganisms.   InMed President, Eric Adams, explained that through synthesis, IN/IMLFF could produce a variety of cannabinoids economically, which opens the door for new products.

Adams further noted that InMed was “dedicating substantial resources” to the commercialization of biosynthetic cannabinoid products.

Financials Trend began covering InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF) following its news on Sept 19, 2017, after announcing the filing of patents on biosynthesis of cannabinoids.  At the time we published that story, shares of InMed Pharmaceuticals rose 7% to $0.36.  Now, IN/IMLFF is trading at nearly $0.45.

We noted in our IN/IMLFF story that it was [BIG NEWS to the scientific community], but Mr. Adams clarified that further in yesterday’s press release when he explained how some extracts from marijuana are expensive to produce but through biosynthesis synthetic cannabinoids are just the opposite.

“The biosynthesis process opens up access to drug discovery and therapeutic use of all 90+ cannabinoids, most of which occur in only trace amounts in the plant and cannot be extracted in an economical fashion,” said Adams.

InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF) shares are trading up over 100% since Financials Trend first covered the company.  In that first article, we called InMed Pharmaceutical a “Five Bagger”, noting its gateway price of $0.21 at the time IN/IMLFF announced its patent applications and so far, it’s not disappointing our readers.  Our outlook hasn’t changed, yet we still stress patience in following IN/IMLFF progress.